Seguir
Helmut Butzkueven
Helmut Butzkueven
MSNI Research Group, Dept of Neuroscience, School of Translational Medicine, Monash University
Dirección de correo verificada de monash.edu
Título
Citado por
Citado por
Año
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Nature 476 (7359), 214-219, 2011
29442011
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
International IBD Genetics Consortium (IIBDGC), C Agliardi, L Alfredsson, ...
Nature genetics 45 (11), 1353-1360, 2013
13252013
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity
R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ...
Neurology 64 (7), 1144-1151, 2005
10562005
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
9382018
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study
IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard, R Simmons, ...
Bmj 327 (7410), 316, 2003
7482003
Gait and balance impairment in early multiple sclerosis in the absence of clinical disability
CL Martin, BA Phillips, TJ Kilpatrick, H Butzkueven, N Tubridy, ...
Multiple Sclerosis Journal 12 (5), 620-628, 2006
7192006
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20
Data analysis: Bahlo Melanie 2 Brown Matthew A 6 7 Browning Brian L 20 ...
Nature genetics 41 (7), 824-828, 2009
5322009
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
4612019
Brain health: time matters in multiple sclerosis
G Giovannoni, H Butzkueven, S Dhib-Jalbut, J Hobart, G Kobelt, G Pepper, ...
Multiple sclerosis and related disorders 9, S5-S48, 2016
4522016
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia
IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard, BV Taylor, T Kilpatrick, ...
Journal of neurology 254, 581-590, 2007
4362007
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
3912016
Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci
NA Patsopoulos, ...
Annals of neurology 70 (6), 897-912, 2011
3602011
LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival
H Butzkueven, JG Zhang, M Soilu-Hanninen, H Hochrein, F Chionh, ...
Nature medicine 8 (6), 613-619, 2002
3192002
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ...
The Lancet Neurology 19 (4), 307-316, 2020
2902020
Geographical variations in sex ratio trends over time in multiple sclerosis
M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ...
PloS one 7 (10), e48078, 2012
2612012
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
D Cadavid, L Balcer, S Galetta, O Aktas, T Ziemssen, L Vanopdenbosch, ...
The Lancet Neurology 16 (3), 189-199, 2017
2572017
Onset seizures independently predict poor outcome after subarachnoid hemorrhage
H Butzkueven, AH Evans, A Pitman, C Leopold, DJ Jolley, AH Kaye, ...
Neurology 55 (9), 1315-1320, 2000
2542000
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis
MS Stein, Y Liu, OM Gray, JE Baker, SC Kolbe, MR Ditchfield, GF Egan, ...
Neurology 77 (17), 1611-1618, 2011
2402011
MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis
H Butzkueven, J Chapman, E Cristiano, F Grand’Maison, M Hoffmann, ...
Multiple Sclerosis Journal 12 (6), 769-774, 2006
2202006
Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis
S Simpson-Yap, E De Brouwer, T Kalincik, N Rijke, JA Hillert, C Walton, ...
Neurology 97 (19), e1870-e1885, 2021
2142021
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20